Category - Developments

Developments

IntelGenx adds Kawartha Centre to Montelukast VersaFilm clinical trial sites

The Kawartha Centre has agreed to participate in IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD).

June 19, 2019

Developments

Xeris Pharma reports additional Phase 3 data for ready-to-use glucagon

Xeris Pharmaceuticals (NASDAQ:XERS) reported positive additional results from its global Phase 3 trial of ready-to-use (RTU) liquid glucagon.

June 18, 2019

Developments

G1 Therapeutics reports updated Phase 2 trial results in triple negative breast cancer

G1 Therapeutics (NASDAQ:GTHX) reported preliminary overall survival results from a Phase 2 trial of trilaciclib in women with metastatic triple-negative breast cancer (mTNBC).

June 18, 2019

Developments

Eiger gets FDA breakthrough therapy designation for avexitide

Eiger BioPharmaceuticals’ (NASDAQ:EIGR) avexitide received FDA breakthrough therapy designation for the treatment of post-bariatric hypoglycemia (PBH).

June 18, 2019

Developments

PhaseBio Pharma reports positive initial Phase 2a results for antiplatelet reversal drug

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported initial results from its Phase 2a trial assessing PB2452’s ability to reverse the effects of the antiplatelet drug, ticagrelor, in subjects 50-to-80 years of age.

June 18, 2019

Developments

Lutronic Vision’s R:GEN laser treats first CSC patient at Seoul National University Hospital

Closely-held Lutronic Vision’s R:GEN laser has treated its first central serous chorioretinopathy (CSC) patient at Seoul National University Hospital (SNUH).

June 18, 2019

Developments

Ocutrx Vision reports enhanced functional vision in AMD patients using Oculenz headset

Closely-held Ocutrx Vision Technologies reported that its augmented reality (AR) glasses significantly improved functional vision compared with standard near correction glasses, or no correction, in subjects with...

June 17, 2019

Developments

ContraVir posts positive human liver results from NASH drug candidate

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported positive findings from its first study with human precision cut liver slice cultures.

June 17, 2019

Developments

Enanta Pharma reports topline results from Phase 2a RSV trial

Enanta Pharmaceuticals (NASDAQ:ENTA) reported that, compared with placebo, EDP-938 significantly reduced viral load and resolved clinical symptoms in healthy adults infected with respiratory syncytial virus (RSV).

June 14, 2019

Developments

Karyopharm Therapeutics reports new selinexor combination data in multiple myeloma

Karyopharm Therapeutics (NASDAQ:KPTI) provided new and updated data from its Phase 1b/2 study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma (MM) therapies.

June 14, 2019

Category - Developments

IntelGenx adds Kawartha Centre to Montelukast VersaFilm clinical trial sites

Xeris Pharma reports additional Phase 3 data for ready-to-use glucagon

G1 Therapeutics reports updated Phase 2 trial results in triple negative breast cancer

Eiger gets FDA breakthrough therapy designation for avexitide

PhaseBio Pharma reports positive initial Phase 2a results for antiplatelet reversal drug

Lutronic Vision’s R:GEN laser treats first CSC patient at Seoul National University Hospital

Ocutrx Vision reports enhanced functional vision in AMD patients using Oculenz headset

ContraVir posts positive human liver results from NASH drug candidate

Enanta Pharma reports topline results from Phase 2a RSV trial

Karyopharm Therapeutics reports new selinexor combination data in multiple myeloma

General

More